FDA clears IntraLuminal's total occlusion guide wire:
This article was originally published in Clinica
IntraLuminal Therapeutics has received US FDA 510(k) clearance to market the first of several generations of its total occlusion products, the Safe-Steer guide wire system. The product is designed to give the cardiologist real-time feedback as to the proximity of the crossing wire to the arterial wall. This should facilitate safe and successful passage through the total occlusion and placement of therapeutic catheters for recanalisation in native coronary arteries, says the Carlsbad, California firm. The market for products designed to cross and recanalise total occlusions is worth $1 billion, the company adds.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.